文献速递心力衰竭与心肌病

维立西呱对代偿性HFrEF门诊患者总体心衰事件的影响:VICTOR研究分析

Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.
PubMed 文献 · J Am Coll Cardiol · 2025-08-27

VICTOR试验纳入6105例近期未恶化的代偿性HFrEF门诊患者,随机接受维立西呱或安慰剂。门诊心衰恶化是首次恶化事件最常见形式(59.3%),且与死亡率升高相关(RR 1.69)。探索性分析显示维立西呱可能降低总体心衰恶化事件(HR 0.90,P=0.047)。

要点

  • 代偿性HFrEF门诊患者中,门诊心衰恶化比住院更常见,且提示死亡风险升高。
  • 维立西呱组总体心衰恶化发生率为22.5%,安慰剂组为24.8%(HR 0.90)。
  • 全因死亡与总体心衰恶化复合终点风险降低(HR 0.90,P=0.016)。

核心结论

  • 在代偿性HFrEF门诊患者中,门诊心衰恶化事件比心衰住院更常见,且与死亡率升高相关。
  • 探索性分析提示维立西呱可能降低总体心衰恶化事件(住院和门诊合计)。

研究设计与样本

  • VICTOR为3期双盲安慰剂对照试验,纳入6105例近期无恶化(6个月内无HHF住院、3个月内无门诊静脉利尿剂)的代偿性HFrEF门诊患者。
  • 患者背景为当代指南治疗高使用率,主要终点为心血管死亡或HHF复合终点。
  • 本次分析纳入门诊心衰恶化事件(紧急静脉利尿剂就诊、门诊口服利尿剂启用或强化)与住院事件。

主要发现

  • 首次恶化事件中门诊心衰恶化851例(59.3%),HHF 507例(35.4%),紧急HF就诊76例(5.3%)。
  • 门诊口服利尿剂启用或强化与死亡率升高相关(RR 1.69;95%CI 1.47-1.94;P<0.001)。
  • 总体心衰恶化:维立西呱组686例(22.5%),安慰剂组748例(24.8%)(HR 0.90;95%CI 0.81-1.00;P=0.047)。
  • 全因死亡与总体心衰恶化复合终点:维立西呱组917例(30.0%),安慰剂组1004例(32.9%)(HR 0.90;95%CI 0.82-0.98;P=0.016)。

临床怎么用

  • 在代偿性HFrEF门诊患者中评估心衰恶化时,应关注门诊口服利尿剂启用或强化等事件,因其与死亡风险升高相关。
  • 维立西呱对总体心衰恶化事件的探索性获益需进一步验证,临床决策应结合主要终点结果综合判断。

局限性

  • 门诊心衰恶化事件的判定依赖利尿剂调整等间接指标,可能存在分类偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the VICTOR (Vericiguat Global Study in Participants With Chronic Heart Failure) trial, in a contemporary ambulatory cohort with heart failure and reduced ejection fraction (HFrEF) and no recent hospitalization, the primary outcome of hospitalization for heart failure (HHF) and cardiovascular death was not statistically significantly reduced with vericiguat. Vericiguat reduced risk of mortality but not HHF. In this ambulatory compensated cohort, time to first HHF may underestimate the overall worsening HF burden by failing to consider the high proportion of outpatient worsening HF events. OBJECTIVES: This study aimed to determine the effect of vericiguat on the overall risk of worsening HF by incorporating the entire patient experience of worsening outpatient and inpatient HF episodes. METHODS: VICTOR was a phase 3, double-blind, placebo-controlled trial testing the effect of vericiguat in ambulatory patients with HFrEF who had not experienced recent worsening (defined as HHF admission within 6 months or outpatient intravenous diuretic use within 3 months) and were on a background of high use of contemporary guideline therapy. The primary endpoint was a composite of cardiovascular death or HHF. The current analysis provides detailed effects of vericiguat on overall worsening HF in both the inpatient and outpatient settings, including urgent care visits for intravenous diuretics or outpatient oral diuretic initiation or intensification. RESULTS: A total of 6,105 participants were randomized. Outpatient worsening HF was more common as the first worsening HF event (n = 851, 59.3%), compared with HHF (n = 507, 35.4%) or urgent HF visits (n = 76, 5.3%). Outpatient oral diuretic initiation or intensification was associated with increased mortality (RR: 1.69; 95% CI: 1.47-1.94; P < 0.001). Overall worsening HF occurred in 686 participants (22.5%) in the vericiguat group and 748 participants (24.8%) in the placebo group (HR: 0.90; 95% CI: 0.81-1.00; P = 0.047). The composite of all-cause death and overall worsening HF occurred in 917 participants (30.0%) in the vericiguat group and 1,004 participants (32.9%) in the placebo group (HR: 0.90; 95% CI: 0.82-0.98; P = 0.016). CONCLUSIONS: In compensated patients with HFrEF on contemporary guideline therapy, worsening HF in outpatients was more common than HHF and was associated with higher risk of mortality. Exploratory analyses suggested a potential reduction in overall worsening HF events when both inpatient and outpatient settings were considered.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Zannad F, Reddy YNV, Barash I, et al. Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR. J Am Coll Cardiol. 2025. PMID: 40892609. doi:10.1016/j.jacc.2025.08.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。